Stężenie sHLA-G i sRCAS1 w osoczu kobiet leczonych operacyjnie z powodu raka sromu jako wskaźnik stanu mikrośrodowiska raka

• Authors: Paweł Blecharz , Joanna Skręt-Magierło , Paweł Basta , Marek Grabiec , Małgorzata Walentynowicz , Zbigniew Kojs , Andrzej Skręt , Łukasz Wicherek

Title variants

EN

Possible usage of the blood serum concentration measurements of sHLA-G and sRCAS1 in women treated surgically for vulvar cancer as an indicator of the status of the tumor microenvironment

• Languages of publication: EN PL

Abstracts

EN

Introduction: The suppression of the immune system constitutes a crucial event in the development of malignancy. Assessment of the blood serum concentration levels of sRCAS1 and sHLA-G may demonstrate the suppressive influence of cancer cells on the immune system as these proteins are involved in the evasion of immune system surveillance by cancer cells. Since, in some cases, surgery may restore proper immune system activity, we aimed to measure the blood serum concentration levels of both these proteins over the course of the applied therapy. Material and methods: We measured the sRCAS1 and sHLA-G blood serum concentration levels in a group of 19 patients treated surgically for vulvar carcinoma. We assessed the levels of these proteins by a series of measurements taken before and after the surgical intervention. The concentration levels of sRCAS1 and sHLA-G were established by means of ELISA kit. Results: In our study we observed that a statistically significant decrease in both sHLA-G and sRCAS1 blood serum concentration levels followed radical surgical intervention due to vulvar cancer. Conclusions: The detected levels of the blood serum concentration of these proteins may be a useful indicator of the status of the tumor microenvironment and may help to assess the degree of restoration of immune system activity following radical surgical vulvectomy.

PL

Wstęp: Supresja układu odpornościowego stanowi kluczowe zjawisko w rozwoju nowotworu złośliwego. Stężenie sRCAS1 i sHLA-G w osoczu odzwierciedla stopień supresji układu odpornościowego przez komórki rakowe, ponieważ białka te pośredniczą w mechanizmie chroniącym komórki rakowe przed wykryciem przez układ odpornościowy. W niektórych przypadkach zabieg chirurgiczny może przywrócić prawidłową aktywność układu odpornościowego, dlatego celem autorów niniejszej pracy była ocena stężenia obu tych białek w trakcie leczenia. Materiał i metody: Mierzono stężenie sRCAS1 i sHLA-G w osoczu 19 pacjentek leczonych operacyjnie z powodu raka sromu. Poziom tych białek oceniano za pomocą serii pomiarów dokonanych przed i po zabiegu operacyjnym. Pomiarów dokonywano za pomocą zestawu wykorzystującego technikę ELISA. Wyniki: Stwierdzono statystycznie znamienny spadek stężenia osoczowego zarówno sRCAS1, jak i sHLA-G po radykalnym usunięciu raka sromu. Wnioski: Poziom ww. białek w osoczu może stanowić przydatny wskaźnik stanu mikrośrodowiska guza i może pomóc ocenić stopień normalizacji aktywności układu odpornościowego po radykalnej operacji sromu.

Keywords

EN

mikrośrodowisko raka; radical vulvectomy; radykalna operacja sromu; rak sromu; sHLA-G; sRCAS1; tumor microenvironment; vulvar cancer

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2009
• Volume: 7
• Issue: 3
• Pages: 192-198

Contributors

author

Paweł Blecharz

• Centrum Onkologii, Klinika Onkologii Ginekologicznej, Instytut im. Marii Curie-Skłodowskiej, Kraków

author

Joanna Skręt-Magierło

• Klinika Położnictwa i Ginekologii, Szpital Wojewódzki, Rzeszów

author

Paweł Basta

• Klinika Ginekologii i Onkologii, Uniwersytet Jagielloński, Kraków

author

Marek Grabiec

• Klinika Ginekologii i Onkologii, Centrum Onkologii im. Łukaszczyka, Bydgoszcz; Katedra Ginekologii, Onkologii i Pielęgniarstwa Ginekologicznego, Kolegium Medyczne im L. Rydygiera, Uniwersytet im. Mikołaja Kopernika, Bydgoszcz

author

Małgorzata Walentynowicz

• Klinika Ginekologii i Onkologii, Centrum Onkologii im. Łukaszczyka, Bydgoszcz; Katedra Ginekologii, Onkologii i Pielęgniarstwa Ginekologicznego, Kolegium Medyczne im L. Rydygiera, Uniwersytet im. Mikołaja Kopernika, Bydgoszcz

author

Zbigniew Kojs

• Centrum Onkologii, Klinika Onkologii Ginekologicznej, Instytut im. Marii Curie-Skłodowskiej, Kraków

author

Andrzej Skręt

• Klinika Położnictwa i Ginekologii, Szpital Wojewódzki, Rzeszów

author

Łukasz Wicherek

• Klinika Ginekologii i Onkologii Uniwersytetu Jagiellońskiego, ul. Kopernika 23, 31-501 Kraków, tel.: [phone], faks: 012 424 85 84. Klinika Ginekologii i Onkologii, Centrum Onkologii im. Łukaszczyka, Bydgoszcz; Katedra Ginekologii, Onkologii i Pielęgniarstwa Ginekologicznego, Kolegium Medyczne im L. Rydygiera, Uniwersytet im. Mikołaja Kopernika, Bydgoszcz

References

• 1. Kovats S., Main E.K., Librach C. i wsp.: A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248: 220-223.
• 2. Pistoia V., Morandi F., Wang X., Ferrone S.: Soluble HLA-G: are they clinically relevant? Semin. Cancer Biol. 2007; 17: 469-479.
• 3. Rebmann V., Regel J., Stolke D., Grosse-Wilde H.: Secretion of sHLA-G molecules in malignancies. Semin. Cancer Biol. 2003; 13: 371-377.
• 4. Rebmann V., Wagner S., Grosse-Wilde H.: HLA-G expression in malignant melanoma. Semin. Cancer Biol. 2007; 17: 422-429.
• 5. Urosevic M., Kurrer M.O., Kamarashev J. i wsp.: Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 2001; 159: 817-824.
• 6. Davidson B., Elstrand M.B., McMaster M.T. i wsp.: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol. 2005; 96: 42-47.
• 7. Singer G., Rebmann V., Chen Y.C. i wsp.: HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 2003; 9: 4460-4464.
• 8. Lindaman A., Dowden A., Zavazava N.: Soluble HLA-G molecules induce apoptosis in natural killer cells. Am. J. Reprod. Immunol. 2006; 56: 68-76.
• 9. Lila N., Rouas-Freiss N., Dausset J. i wsp.: Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc. Natl Acad. Sci. USA 2001; 98: 12150-12155.
• 10. Fournel S., Aguerre-Girr M., Huc X. i wsp.: Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J. Immunol. 2000; 164: 6100-6104.
• 11. Sheu B.C., Chiou S.H., Lin H.H. i wsp.: Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res. 2005; 65: 2921-2929.
• 12. Sheu B.C., Lin R.H., Lien H.C. i wsp.: Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J. Immunol. 2001; 167: 2972-2978.
• 13. Sonoda K., Miyamoto S., Hirakawa T. i wsp.: Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol. Oncol. 2005; 97: 772-779.
• 14. Sonoda K., Miyamoto S., Hirakawa T. i wsp.: Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol. Oncol. 2005; 99: 189-198.
• 15. Sonoda K., Miyamoto S., Hirakawa T. i wsp.: Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol. Oncol. 2006; 103: 924-931.
• 16. Dutsch-Wicherek M., Wicherek L.: The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am. J. Reprod. Immunol. 2008; 59: 266-275.
• 17. Wicherek L.: Alterations in RCAS1 serum concentration levels during the normal menstrual cycle and the lack of analogical changes in ovarian endometriosis. Am. J. Reprod. Immunol. 2008; 59: 535-544.
• 18. Arruvito L., Sanz M., Banham A.H., Fainboim L.: Expansion of CD4+CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J. Immunol. 2007; 178: 2572-2578.
• 19. Wilczynski J.R., Kalinka J., Radwan M.: The role of T-regulatory cells in pregnancy and cancer. Front. Biosci. 2008; 13: 2275-2289.
• 20. Wilczynski J.R., Radwan M., Kalinka J.: The characterization and role of regulatory T cells in immune reactions. Front. Biosci. 2008; 13: 2266-2274.
• 21. Matsushima T., Nakashima M., Oshima K. i wsp.: Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 2001; 98: 313-321.
• 22. Sonoda K., Kaku T., Hirakawa T. i wsp.: The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol. Oncol. 2000; 79: 424-429.
• 23. Nakashima M., Sonoda K., Watanabe T.: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat. Med. 1999; 5: 938-942.
• 24. Akahira J.I., Aoki M., Suzuki T. i wsp.: Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. Br. J. Cancer 2004; 90: 2197-2202.
• 25. Ito Y., Yoshida H., Nakano K. i wsp.: Overexpression of human tumor-associated antigen, RCAS1, is significantly linked to dedifferentiation of thyroid carcinoma. Oncology 2003; 64: 83-89.
• 26. Wicherek L., Popiela T.J., Galazka K. i wsp.: Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes. Gynecol. Oncol. 2005; 99: 622-630.
• 27. Aoki T., Inoue S., Imamura H. i wsp.: EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur. J. Cancer 2003; 39: 1552-1561.
• 28. Özkan H., Akar T., Köklü S., Çoban Ş.: Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 2006; 6: 268-272.
• 29. Nakakubo Y., Hida Y., Miyamoto M. i wsp.: The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett. 2002; 177: 101-105.
• 30. Rousseau J., Têtu B., Caron D. i wsp.: RCAS1 is associated with ductal breast cancer progression. Biochem. Biophys. Res. Commun. 2002; 293: 1544-1549.
• 31. Leelawat K., Watanabe T., Nakajima M. i wsp.: Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J. Clin. Pathol. 2003; 56: 764-768.
• 32. Nakamura Y., Yamazaki K., Oizumi S. i wsp.: Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci. 2004; 95: 260-265.
• 33. Enjoji M., Nakashima M., Yamaguchi K. i wsp.: Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas. J. Gastroenterol. Hepatol. 2005; 20: 1143-1148.
• 34. Kato H., Nakajima M., Masuda N. i wsp.: Expression of RCAS1 in esophageal squamous cell carcinoma is associated with a poor prognosis. J. Surg. Oncol. 2005; 90: 89-94.
• 35. Akashi T., Oimomi H., Nishiyama K. i wsp.: Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas 2003; 26: 49-55.
• 36. Yamaguchi K., Enjoji M., Nakashima M. i wsp.: Novel serum tumor marker, RCAS1, in pancreatic diseases. World J. Gastroenterol. 2005; 11: 5199-5202.
• 37. Enjoji M., Yamaguchi K., Nakashima M. i wsp.: Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Liver Int. 2004; 24: 330-334.
• 38. Dutsch-Wicherek M., Popiela T.J., Wicherek L. i wsp.: RCAS1 expression in laryngeal and pharyngeal cancer with local lymph node metastasis. W: Papaspyrou S. (red.): 5th European Congress of Oto-Rhino-Laryngology Head and Neck Surgery. Rodos (Greece), September 11-16, 2004. Medimond S.r.l., Bologna 2004: 345-348.
• 39. Eidukaite A., Tamosiunas V.: Soluble HLA-G in the peritoneal fluid of women with endometriosis. Fertil. Steril. 2008; 89: 465-467.
• 40. Kawashima M., Maeda N., Adachi Y. i wsp.: Human leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is expressed by eutopic endometrium only in the menstrual phase. Fertil. Steril. 2009; 91: 343-349.
• 41. Barrier B.F., Kendall B.S., Ryan C.E., Sharpe-Timms K.L.: HLA-G is expressed by the glandular epithelium of peritoneal endometriosis but not in eutopic endometrium. Hum. Reprod. 2006; 21: 864-869.
• 42. Wang F., Wen Z., Li H. i wsp.: Human leukocyte antigen-G is expressed by the eutopic and ectopic endometrium of adenomyosis. Fertil. Steril. 2008; 90: 1599-1604.
• 43. Carosella E.D., Moreau P., Le Maoult J. i wsp.: HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 2003; 81: 199-252.
• 44. Rouas-Freiss N., Naji A., Durrbach A., Carosella E.D.: Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 2007; 84 (supl.): S21-S25.
• 45. Wicherek L.: The role of the endometrium in the regulation of immune cell activity. Front. Biosci. 2008; 13: 1018-1035.
• 46. Knafel A., Basta P., Pitynski K. i wsp.: Soluble HLA-G changes in maternal blood serum during the progression of labor. Neuro Endocrinol. Lett. 2009; 30: 67-73.
• 47. Wicherek L., Basta P., Pitynski K. i wsp.: The characterization of the subpopulation of suppressive B7H4+ macrophages and the subpopulation of CD25+ CD4+ and FOXP3+ regulatory T-cells in decidua during the secretory cycle phase, Arias Stella reaction, and spontaneous abortion – a preliminary report. Am. J. Reprod. Immunol. 2009; 61: 303-312.
• 48. Wicherek L., Basta P., Galazka K. i wsp.: RCAS1 decidual immunoreactivity and RCAS1 serum level during cesarean section with respect to the progression of labor. Am. J. Reprod. Immunol. 2008; 59: 152-158.
• 49. Wilczyński J.R.: Cancer and pregnancy share similar mechanisms of immunological escape. Chemotherapy 2006; 52: 107-110.
• 50. Siedlar M.: Areaktywność monocytów człowieka indukowana przez bakteryjne czynniki prozapalne i komórki nowotworowe. Rozprawa habilitacyjna UJCM. JB Lakmal, Bytom 2006.
• 51. Chen R., Alvero A.B., Silasi D.A., Mor G.: Inflammation, cancer and chemoresistance: taking advantage of the Toll-like receptor signaling pathway. Am. J. Reprod. Immunol. 2007; 57: 93-107.
• 52. Emens L.A.: Chemotherapy and tumor immunity: an unexpected collaboration. Front. Biosci. 2008; 13: 249-257.
• 53. Salvadori S., Martinelli G., Zier K.: Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 2000; 164: 2214-2220.
• 54. Côté A.L., Usherwood E.J., Turk M.I.: Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res. 2008; 68: 1614-1617.
• 55. Pollard J.W.: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004; 4: 71-78.
• 56. Lin E.Y., Pollard J.W.: Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007; 67: 5064-5066.
• 57. Condeelis J., Pollard J.W.: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
• 58. Lin E.Y., Pollard J.W.: Role of infiltrated leucocytes in tumour growth and spread. Br. J. Cancer 2004; 90: 2053-2058.

• Document Type: article